Clinical trial
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute…
NCT00136448 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00136448 |
|---|---|
| Title | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) |
| Official title | High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | cytosine arabinoside (ara-C), daunomycin, interleukin-2 |
| Enrollment | 30 |
| Start date | Feb 1, 1993 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Aug 29, 2005 |
| Last update posted | Mar 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: